Joint Position Statement from the National Psoriasis Foundation Medical Board and the International Psoriasis Council on Routine Testing for Latent Tuberculosis Infection Prior To and During Treatment of Psoriasis Patients with IL-17 or IL-23 Inhibitors

By afschroeder • November 20, 2025

Blauvelt A, Strober BE, Eakin GS, McCormick Howard L, Langan C, van de Kerkhof PCM, Puig L, Lebwohl MG, Romiti R, Armstrong AW, Choon SE, Ramessur R, Gelfand JM, Merola JF, Winthrop KL, Torres T. Joint Position Statement from the National Psoriasis Foundation Medical Board and the International Psoriasis Council on Routine Testing for Latent Tuberculosis Infection Prior To and During Treatment of Psoriasis Patients with IL-17 or IL-23 Inhibitors. J Am Acad Dermatol. 2025 Nov 17:S0190-9622(25)03232-3. doi: 10.1016/j.jaad.2025.11.033. Epub ahead of print. PMID: 41260526.

Tags: Dermatology, Publications

A Response to: “Letter to the Editor Regarding ‘Anchored Matching-Adjusted Indirect Comparison of the Long-Term Maintenance of Efficacy of Tralokinumab and Lebrikizumab in Patients with Moderate-to-Severe Atopic Dermatitis'”

Augustin M, Armstrong AW, Issa NT, Petersen AS, von Eyben R, Festini T, Torres T. A Response to: "Letter to the Editor Regarding 'Anchored Matching-Adjusted[...]

Long-term disability outcomes in Hansen’s disease: A 20-year comparative study of Lepromatous vs. Tuberculoid Leprosy

Ma EJ, Adler BL, Armstrong AW, Ochoa MT. Long-term disability outcomes in Hansen's disease: A 20-year comparative study of Lepromatous vs. Tuberculoid Leprosy. PLoS Negl[...]

Impact of Online vs In-Person Management of Atopic Dermatitis on Quality of Life and Access to Care: A Randomized Controlled Trial

Armstrong AW, Roberts AM, Kostandy G, Choudhury F, Yee D, Luu M, Jones ME, Alizadeh ER, Cotliar J, Chren MM, Gelfand JM, Cockburn M, Doctor[...]